Furthermore, we analyzed the site of metastasis in 22 patients with advanced stage NSCLC, including four patients with ALK rearrangements, two with EGFR mutations, one with ROS1 mutations and 15 with unknown driver oncogenes. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.